IMPACT OF SEMAGLUTIDE VERSUS TIRZEPATIDE ON WEIGHT AND BODY MASS INDEX IN PATIENTS WITH POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS): ANALYSIS OF US REAL-WORLD DATA
Author(s)
Janna Manjelievskaia, MPH, PhD, Isabelle Winer, PhD, Robert Sedgley, MS, Maryam Ajose, MPH, Jessamine Winer-Jones, PhD, anusorn thanataveerat, DrPH.
Veradigm, Raleigh, NC, USA.
Veradigm, Raleigh, NC, USA.
OBJECTIVES: PMOS is a multifactorial metabolic and endocrine condition affecting a substantial proportion of the female population. Off-label use of incretin mimetics has shown promising metabolic benefits in patients with PMOS. Here, we assessed the impact of semaglutide vs tirzepatide on weight, BMI, and A1c in patients with PMOS.
METHODS: This study used the Veradigm Network EHR linked to Merative MarketScan claims to identify patients 12-50 years identified as female with diagnosed PMOS. Patients were required to have a prescription for semaglutide or tirzepatide between 01/01/2020-03/31/2025 (earliest prescription=index). Inclusion criteria were ≥1 year of continuous enrollment pre- (baseline) and post-index (follow-up) and no evidence of pregnancy/delivery or bariatric surgery. Changes in weight, BMI, and A1c from baseline to follow-up were captured among IPTW-adjusted cohorts. Outcomes were examined per-protocol (primary analysis) and a modified intention-to-treat (sensitivity analysis).
RESULTS: Final matched cohorts included 870 semaglutide and 235 tirzepatide patients. Mean (SD) age was 39(8.0) years and majority were White (58%). In the primary analysis, for semaglutide patients, mean baseline weight and BMI was 233.1 lbs and 36.5 kg/m2, respectively; mean baseline A1c was 6.7%. For tirzepatide patients, mean baseline weight, BMI, and A1c was 231.7 lbs, 36.4 kg/m2, and 6.6%, respectively. During follow-up (primary analysis), patients on semaglutide had an observed 6.5% reduction in weight vs an 8.5% among tirzepatide patients. Among changes in BMI, mean levels reduced by 4.8% for those taking semaglutide vs 8.0% among tirzepatide patients. A1c levels decreased by 12.4% and 14.5% for semaglutide and tirzepatide. Sensitivity analysis showed similar trends.
CONCLUSIONS: Our analysis of patients with PMOS on semaglutide vs tirzepatide highlighted marked improvements across weight, BMI, and A1C values. Patients on tirzepatide saw more substantial changes to their metabolic markers as compared to semaglutide.
METHODS: This study used the Veradigm Network EHR linked to Merative MarketScan claims to identify patients 12-50 years identified as female with diagnosed PMOS. Patients were required to have a prescription for semaglutide or tirzepatide between 01/01/2020-03/31/2025 (earliest prescription=index). Inclusion criteria were ≥1 year of continuous enrollment pre- (baseline) and post-index (follow-up) and no evidence of pregnancy/delivery or bariatric surgery. Changes in weight, BMI, and A1c from baseline to follow-up were captured among IPTW-adjusted cohorts. Outcomes were examined per-protocol (primary analysis) and a modified intention-to-treat (sensitivity analysis).
RESULTS: Final matched cohorts included 870 semaglutide and 235 tirzepatide patients. Mean (SD) age was 39(8.0) years and majority were White (58%). In the primary analysis, for semaglutide patients, mean baseline weight and BMI was 233.1 lbs and 36.5 kg/m2, respectively; mean baseline A1c was 6.7%. For tirzepatide patients, mean baseline weight, BMI, and A1c was 231.7 lbs, 36.4 kg/m2, and 6.6%, respectively. During follow-up (primary analysis), patients on semaglutide had an observed 6.5% reduction in weight vs an 8.5% among tirzepatide patients. Among changes in BMI, mean levels reduced by 4.8% for those taking semaglutide vs 8.0% among tirzepatide patients. A1c levels decreased by 12.4% and 14.5% for semaglutide and tirzepatide. Sensitivity analysis showed similar trends.
CONCLUSIONS: Our analysis of patients with PMOS on semaglutide vs tirzepatide highlighted marked improvements across weight, BMI, and A1C values. Patients on tirzepatide saw more substantial changes to their metabolic markers as compared to semaglutide.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO191
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment, Comparative Effectiveness or Efficacy
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas